Traws Pharma
TRAW
13 hedge funds and large institutions have $22.5M invested in Traws Pharma in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 11 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
278% more capital inflows, than outflows
Capital inflows: $872K | Capital outflows: $231K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.36% less ownership
Funds ownership: 56.48% → 54.12% (-2.4%)
43% less funds holding
Funds holding: 23 → 13 (-10)
91% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$686K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$112K |
| 3 |
Panagora Asset Management
Boston,
Massachusetts
|
+$40.8K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$10.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DRW Securities
Chicago,
Illinois
|
-$61K |
| 2 |
Clear Harbor Asset Management
Stamford,
Connecticut
|
-$51K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$26K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$22K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$20K |
TRAW Hedge Fund Activity: Q3 2018 in Review
13 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q3 2018, worth a combined $22.5M — up 25% from $18.1M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TRAW and 1 opened new positions — a net loss of 10 holders — while 1 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $686K. The largest seller was DRW Securities, exiting entirely with an estimated $61K sold.
- 13 institutional investors held Traws Pharma (TRAW) as of Q3 2018, down from 23 in Q2 2018.
- Funds reported $22.5M of Traws Pharma stock for Q3 2018, up 25% quarter-over-quarter.
- 1 fund opened new Traws Pharma positions in Q3 2018 and 11 closed out, a net change of -10 holders.
- The largest Traws Pharma buyer in Q3 2018 was Vanguard Group, an estimated $686K added.
- The largest Traws Pharma seller in Q3 2018 was DRW Securities, an estimated $61K sold.
Based on aggregated 13F filings for Q3 2018.